
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Long-term data show avapritinib cuts systemic mastocytosis burden, delivers lasting responses, manageable safety, and boosts bone health markers.
Avapritinib demonstrated durable clinical activity in advanced systemic mastocytosis, with sustained reductions in disease burden and consistent responses across subtypes over long-term follow-up. Treatment was generally well tolerated, with a safety profile aligned with prior experience and manageable adverse events. Improvements in bone health markers and density suggest a potential disease-modifying effect beyond hematologic control.






